Long-term management of patients after venous thromboembolism

Circulation

Volumn 110, Issue 9 SUPPL., 2004, Pages

  Kearon, Clive ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Anticoagulant therapy; Deep vein thrombosis; Pulmonary embolism; Warfarin

Indexed keywords

ANTIVITAMIN K; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; THROMBIN INHIBITOR; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER; CANCER RISK; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; RECURRENCE; THROMBOEMBOLISM; VENOUS THROMBOSIS; VITAMIN K;

EID: 4544290175     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000140902.46296.ae     Document Type: Review

References (98)

1. Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet. 1992;340:873-876.
2. Levine MN, Hirsh J, Gent M, et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995;74:606-611.
3. Schulman S, Rhedin A-S, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med. 1995;332:1661-1665.
4. Prandoni P, Lensing AWA, Buller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med. 1992;327:1128-1133.
5. Pini M, Aiello S, Manotti C, et al. Low molecular weight heparin versus warfarin the prevention of recurrence after deep vein thrombosis. Thromb Haemost. 1994;72:191-197.
6. Palareti G, Legnani C, Cosmi B, et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost. 2002;87:7-12.
7. Baglin T, Luddington R, Brown K, et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362:523-526.
8. Kearon C, Gent M, Hirsh J, et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901-907.
9. Palareti G, Legnani C, Cosmi B, et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation. 2003;108:313-318.
10. Prandoni P, Lensing AWA, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
11. Ridker PM, Miletich JP, Stampfer MJ, et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation. 1995;92:2800-2802.
12. 506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997;336:399-403.
13. Eichinger S, Pabinger I, Stumpflen A, et al. The risk of recurrent venous thromboembolism in patients with and without Factor V Leiden. Thromb Haemost. 1997;77:624-628.
14. Lindmarker P, Schulman S, Sten-Linder M, et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A Allele in the coagulation factor V gene and the G20210A Allele in the prothrombin gene. Thromb Haemost. 1999;81:684-689.
15. Miles JS, Miletich JP, Goldhaber SZ, et al. G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism. J Am Coll Cardiol. 2001;37:215-218.
16. Simioni P, Prandoni P, Lensing AW, et al. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood. 2000;96:3329-3333.
17. Eichinger S, Minar E, Hirschl M, et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost. 1999;81:14-17.
18. 20210 gene variant. Ann Intern Med. 1998;129:89-93.
19. DeStefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med. 1999;341:801-806.
20. Kryle P, Minar E, Hirschl M, et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Eng J Med. 2000;343:457-462.
21. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost. 2000;83:5-9.
22. Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med. 1998;104:332-338.
23. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost. 1998;80:566-569.
24. Eichinger S, Minar E, Bialonczyk C, et al. D-dimer levels and risk of recurrent venous thromboembolism. JAMA. 2003;290:1071-1074.
25. Heit JA, Mohr DN, Silverstein MD, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med. 2000;160:761-768.
26. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
27. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med. 2000;132:689-696.
28. Hoibraaten E. Qvigstad E, Arnesen H, et al. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84:961-967.
29. Piovella F, Crippa L, Barone M, et al. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica. 2002;87:515-522.
30. Agnelli G, Prandoni P, Becattini C, et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003;139:19-25.
31. Lindmarker P, Schulman S. The risk of ipsilateral versus contralateral recurrent deep vein thrombosis in the leg. The DURAC Trial Study Group. J Intern Med. 2000;247:601-606.
32. Murin S, Romano PS, White RH, et al. Comparison of outcomes after hospitalization for deep vein thrombosis or pulmonary embolism. Thromb Haemost. 2002;88:407-414.
33. White RH, Zhou H, Kim J, et al. A population-based study of the effectiveness of inferior vena cava filter use among patients with venous thromboembolism. Arch Intern Med. 2000;160:2033-2041.
34. Decousus H, Leizorovicz A, Parent F, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med. 1998;338:409-415.
35. Schulman S, Granqvist S, Holmstrom M, et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med. 1997;336:393-398.
36. Schulman S, Wahlander K, Lundström T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Eng J Med. 2003;349:1713-1721.
37. Pinede L, Ninet J, Duhaut P, et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation. 2001;103:2453-2460.
38. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Eng J Med. 2003;348:1425-1434.
39. Spiezia L, Bernardi E, Tormene D, et al. Recurrent thromboembolism in fertile women with venous thrombosis: incidence and risk factors. Thromb Haemost. 2003;90:964-966.
40. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med. 2000;51:169-185.
41. Lane DA, Mannucci PM, Bauer KA, et al. Inherited Thrombophilia: Part 1. Thromb Haemost. 1996;76:651-662.
42. Lane DA, Mannucci PM, Bauer KA, et al. Inherited Thrombophilia: Part 2. Thromb Haemost. 1996;76:824-834.
43. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999;353:1167-1173.
44. Van den Belt AG, Sanson BJ, Simioni P, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157:2227-2232.
45. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis, Thromb Haemost. 1999;81:165-176.
46. Den Heijer M, Willems HP, Blom HJ, et al. Homocysteine lowering by B vitamins and the prevention of secondary deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. J Thromb Haemost. 2003;1(Suppl 1):OC161.
47. Hutten BA, Prins M, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000;18:3078-3083.
48. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intent Med. 2001;134:191-202.
49. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost. 2000;84:805-810.
50. Douketis JD, Kearon C, Bates S, et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA. 1998;279:458-462.
51. Kniffin WD Jr., Baron JA, Barrett J, et al. The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med. 1994;154:861-866.
52. Agnelli G, Prandoni P, Santamaria MG, et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep vein thrombosis. N Engl J Med. 2001;345:165-169.
53. Bell WR, Simon TL. Current status of pulmonary embolic disease: pathophysiology, diagnosis, prevention, and treatment. Am Heart J. 1982;103:239-262.
54. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest. 1995;108:978-981.
55. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107:122-130.
56. Goldhaber SZ, Visni L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386-1389.
57. Heit JA, Silverstein MD, Mohr DN, et al. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 1999;159:445-453.
58. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, et al. Echocardiography doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J. 1997;134:479-487.
59. Bell CM, Redelmeier DA. Mortality among patients admitted to hospitals on weekends as compared with weekdays. N Engl J Med. 2001;345:663-668.
60. Beyth RJ, Cohen AM, Landefeld CS. Long-term outcomes of deep-vein thrombosis. Arch Intern Med. 1995;155:1031-1037.
61. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med. 2001;345:1465-1472.
62. Prandoni P, Lensing AW, Prins MH, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med. 2002;137:955-960.
63. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349:631-639.
64. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA. 1999;282:2058-2067.
65. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501.
66. White RH, Beyth RJ, Zhou H, et al. Major bleeding after hospitalization for deep-venous thrombosis. Am J Med. 1999;107:414-424.
67. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet. 1996;348:423-428.
68. Linkins L, Choi PT, Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Ann Intern Med. 2003;139:893-900.
69. Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med. 1993;95:315-328.
70. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105:91-99.
71. Kuijer PMM, Hutten BA, Prins MH, et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457-460.
72. Pengo V, Legnani C, Noventa F, et al. Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost. 2001;85:418-422.
73. Massel D, Little SH. Risks and benefits of adding anti-platelet therapy to warfarin among patients with prosthetic heart valves: a meta-analysis. J Am Coll Cardiol. 2001;37:569-578.
74. Poller L, Shiach CR, MacCallum PK, et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet. 1998;352:1505-1509.
75. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med. 2000;133:687-695.
76. Margaglione M, Colaizzo D, D'Andrea G, et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost. 2000;84:775-778.
77. Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717-719.
78. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
79. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology. 1999;53:1319-1327.
80. Hull R, Hirsh J, Jay R, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982;307:1676-1681.
81. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133-1138.
82. Bynum LJ, Wilson JE. Low-dose heparin therapy in the long-term management of venous thromboembolism. Am J Med. 1979;67:553-556.
83. Hull R, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979;301:855-858.
84. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med. 1982;306:189-194.
85. Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11.
86. Das SK. Cohen AT, Edmondson RA, et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg. 1996;20:521-527.
87. Hamann H. Rezidivprophylaxe nach phlebothrombose-orale antikoagulation oder niedermolelulares heparin subkutan. Vasomed. 1998;10:133-136.
88. Lopaciuk S, Bielska-Falda H, Noszczyk W, et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost. 1999;81:26-31.
89. Gonzalez-Fajardo JA, Arveba E, Castrodeza J, et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg. 1999;30:283-292.
90. Veiga F, Escriba A, Maluenda MP, et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost. 2000;84:559-564.
91. Lopez-Beret P, Orgaz A, Fontcuberta J, et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg. 2001;33:77-90.
92. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162:1729-1735.
93. Hull R, Pineo G, Mah A, et al. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood. 2000;96:449a.
94. Hull RD, Pineo GF, Mah AF, et al. A randomized trial evaluating long-term low-molecular weight heparin therapy for three months versus intravenous heparin followed by warfarin. Blood. 2003;100:556a.
95. Kakkar V, Gebska M, Kadziola Z, et al. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost. 2003;89:674-680.
96. Lee AY, Levine MN, Baker RI, et al. A randomized comparison of low-molecular-weight heparin with an oral anticoagulant for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349:146-153.
97. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost. 2003;1:1906-1913.
98. Brandjes DP, Büller HR, Heijboer H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet. 1997;349:759-762.